More questions about Merck's Gardasil published in 'JAMA'

Updated

As if Merck & Co. (MRK) needed more scrutiny of its controversial cervical cancer vaccine, Gardasil.

One of the first cancer vaccines on the market, Gardasil combats human papillomavirus -- a sexually transmitted virus contracted by 80 percent of sexually active women by age 50 -- Gardasil was designed to immunize women before they contract the virus and was approved by the Food and Drug Administration in 2006 for girls and women between 9 and 26. The Advisory Committee on Immunization Practices recommended that girls be vaccinated at ages 11 to 12.

Originally published